Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Mitochondrion-driven nephroprotective mechanisms of novel glucose lowering medications

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Partial inhibition of mitochondrial-linked pyrimidine synthesis increases tumorigenic potential and lysosome accumulation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Plasma lactate responses during and after submaximal handgrip exercise are not diagnostically helpful in mitochondrial myopathy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Growth and differentiation factor 15 as a biomarker for mitochondrial myopathy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Muscle contractility of leg muscles in patients with mitochondrial myopathies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Evaluation of commercially available glucagon receptor antibodies and glucagon receptor expression

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Further perspectives on statin use in patients with chronic kidney disease

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  3. Prevalence of non-alcoholic fatty liver disease in patients with chronic kidney disease: a cross-sectional study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Soluble urokinase plasminogen activator receptor and decline in kidney function among patients without kidney disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Baris Afsar
  • Mads Hornum
  • Rengin Elsurer Afsar
  • Lale A Ertuglu
  • Alberto Ortiz
  • Adrian Covic
  • Daniel H van Raalte
  • David Z I Cherney
  • Mehmet Kanbay
Vis graf over relationer

Therapy for diabetic kidney disease (DKD) is undergoing a revolution with the realization that some glucose-lowering drugs have nephroprotective actions that may be intrinsic to the drugs and not dependent on the impact on diabetes control, as demonstrated with the sodium glucose co-transporter-2 (SGLT-2) inhibitors. Mitochondria are a critical factor required for the maintenance of kidney function, given its high energy demanding profile, with extensive use of adenosine triphosphate (ATP). Consequently, deficiency of the master regulator of mitochondrial biogenesis peroxisome proliferator-activated receptor gamma coactivator 1α predisposes to kidney disease. Perhaps as a result of key role of mitochondria in fundamental cellular functions, mitochondrial dysfunction may play a role in the pathogenesis of common conditions such as DKD. Finding pharmacological agents to influence this pathway could therefore lead to early implementation of therapy. Importantly, glucose-lowering drugs such as glucagon-like peptide-1 receptor activators and SGLT2 inhibitors have kidney and/or cardioprotective actions in patients with diabetes. Accumulating evidence from preclinical studies has suggested a protective effect of these drugs that is in part mediated by normalizing mitochondrial function. We now critically review this evidence and discuss studies needed to confirm mitochondrial protective benefits across a range of clinical studies.

OriginalsprogEngelsk
TidsskriftMitochondrion
Vol/bind58
Sider (fra-til)72-82
Antal sider11
ISSN1567-7249
DOI
StatusUdgivet - maj 2021

Bibliografisk note

Copyright © 2021. Published by Elsevier B.V.

ID: 69765132